{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:40:24Z","timestamp":1793295624419,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003061","name":"Erasmus MC","doi-asserted-by":"publisher","award":["#20926"],"award-info":[{"award-number":["#20926"]}],"id":[{"id":"10.13039\/501100003061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003061","name":"Erasmus MC","doi-asserted-by":"publisher","award":["#111296"],"award-info":[{"award-number":["#111296"]}],"id":[{"id":"10.13039\/501100003061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["#EMCLSH21006"],"award-info":[{"award-number":["#EMCLSH21006"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["EVITA"],"award-info":[{"award-number":["EVITA"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["MIBC-Org # LSHM23065"],"award-info":[{"award-number":["MIBC-Org # LSHM23065"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.euros.2026.07.009","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:20:09Z","timestamp":1789766409000},"page":"3-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer"],"prefix":"10.1016","volume":"93","author":[{"given":"Mathijs P.","family":"Scholtes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmee","family":"Koedoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieke J.","family":"Ceton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.P.","family":"Sijsenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta G.","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caithlyn Z.","family":"Roeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"van Soest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Leijte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Roshani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Korthorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieudonn\u00e9 J.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert J.L.H.","family":"van Leenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn","family":"Vader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost L.","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahlita C.M.","family":"Zuiverloon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.07.009_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.07.009_b0010","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.07.009_b0015","doi-asserted-by":"crossref","first-page":"S1343","DOI":"10.1016\/j.annonc.2023.10.110","article-title":"LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)","volume":"34","author":"Vilaseca","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2026.07.009_b0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euros.2026.07.009_b0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.euo.2020.02.006","article-title":"Evidence-based assessment of current and emerging bladder-sparing therapies for non\u2013muscle-invasive bladder cancer after bacillus Calmette-Guerin therapy: a systematic review and meta-analysis","volume":"3","author":"Kamat","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2026.07.009_b0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.07.009_b0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.07.009_b0040","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.07.009_b0045","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.07.009_b0050","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3233\/BLC-200303","article-title":"Survival of patients with muscle-invasive urothelial cancer of the bladder with residual disease at time of cystectomy: A comparative survival analysis of treatment modalities in the national cancer database","volume":"6","author":"Pfail","year":"2020","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euros.2026.07.009_b0055","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2018.09.004","article-title":"Delaying radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer is associated with adverse survival outcomes","volume":"2","author":"Boeri","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2026.07.009_b0060","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-5347(05)64047-5","article-title":"An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma","volume":"169","author":"S\u00e1nchez-Ortiz","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.07.009_b0065","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1158\/1078-0432.CCR-05-1045","article-title":"A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine","volume":"11","author":"Van Oers","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euros.2026.07.009_b0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1756-0500-2-66","article-title":"A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene","volume":"2","author":"Hurst","year":"2009","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.euros.2026.07.009_b0075","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","article-title":"Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome","volume":"65","author":"Allory","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.07.009_b0080","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41698-025-01080-8","article-title":"Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer","volume":"9","author":"Koedoot","year":"2025","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.euros.2026.07.009_b0085","doi-asserted-by":"crossref","first-page":"623","DOI":"10.4111\/icu.20210265","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer: an abridged Cochrane Review","volume":"62","author":"Han","year":"2021","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.euros.2026.07.009_b0090","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00345-025-05955-0","article-title":"Inlexzo (gemcitabine intravesical system): promising data but key questions remain","volume":"43","author":"Azhar","year":"2025","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2026.07.009_b0095","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.07.009_b0100","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euros.2026.07.009_b0105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.eururo.2024.06.018","article-title":"Correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: results from the SWOG S1314 trial","volume":"86","author":"Plimack","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.07.009_b0110","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euros.2026.07.009_b0115","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.07.009_b0120","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/1078-0432.CCR-23-0602","article-title":"Association of molecular subtypes with pathologic response, PFS, and OS in a Phase II study of COXEN with neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"30","author":"Lerner","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euros.2026.07.009_b0125","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","article-title":"Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders","volume":"12","author":"Kornauth","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euros.2026.07.009_b0130","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a functional precision medicine tumor board for acute myeloid leukemia","volume":"12","author":"Malani","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euros.2026.07.009_b0135","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/s43018-023-00645-5","article-title":"Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial","volume":"4","author":"Liebers","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.euros.2026.07.009_b0140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41523-023-00583-6","article-title":"Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients","volume":"9","author":"Ladan","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.euros.2026.07.009_b0145","article-title":"Unified framework for patient-derived, tumor-organoid-based predictive testing of standard-of-care therapies in metastatic colorectal cancer","volume":"4","author":"Tan","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.euros.2026.07.009_b0150","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41591-024-02848-4","article-title":"Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers","volume":"30","author":"Acanda De La Rocha","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.euros.2026.07.009_b0155","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41467-023-37696-2","article-title":"Bladder cancer organoids as a functional system to model different disease stages and therapy response","volume":"14","author":"Minoli","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.euros.2026.07.009_b0160","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3389\/fonc.2018.00400","article-title":"An ex vivo tissue culture model for the assessment of individualized drug responses in prostate and bladder cancer","volume":"8","author":"Van De Merbel","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.euros.2026.07.009_b0165","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor evolution and drug response in patient-derived organoid models of bladder cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.euros.2026.07.009_b0170","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.eururo.2024.05.026","article-title":"Integrative drug screening and multiomic characterization of patient-derived bladder cancer organoids reveal novel molecular correlates of gemcitabine response","volume":"86","author":"Merrill","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.07.009_b0175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12894-023-01262-1","article-title":"Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial","volume":"23","author":"Seiler","year":"2023","journal-title":"BMC Urol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:29:59Z","timestamp":1793294999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326006671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":35,"alternative-id":["S2666168326006671"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.07.009","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}